Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.085
Sell
RSI(14)
35.139
Neutral
STOCH(KDJ)(9,3,3)
21.447
Sell
ATR(14)
0.388
High Vlolatility
CCI(14)
-197.164
Sell
Williams %R
89.381
Oversold
TRIX(12,20)
-0.375
Sell
StochRSI(14)
0.000
Oversold
Search
Prothena Corporation PLC
PRTAAdd to Watchlist
8.120USD
-0.290-3.45%
Close 07-31 16:00（ET）Quotes delayed by 15 min
425.11MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-3.45%
5 Days
-7.20%
1 Month
-16.20%
6 Months
-8.87%
Year to Date
-14.97%
1 Year
+19.24%
Key Figures
8.410Open
8.510High
545.49KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.03%Turnover Ratio
8.410Prev. Close
8.000Low
3.22MTurnover
LossP/E Static
1.38P/B
0.00%Div Yield TTM
-35.77%ROA
11.80052wk High
0.85Volume Ratio
-122.31MNet Profit
53.08MShares
-2.8070EPS TTM
-0.25Beta
-40.30%ROE
4.42252wk Low
6.06%Amplitude
100.00%Gross Margin
425.11MMarket Cap
-3.90Reward/Risk
2.94%Risk Rate
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2026-07-31Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.40.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Fairly Valued
The company’s latest PE is -2.89, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.39M shares, decreasing 22.37% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 387.84K shares of this stock.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+163.55%
Upside Space
Prothena Corporation PLC News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+163.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Prothena Corporation PLC
PRTA
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
8.470
Sell
MA10
8.549
Sell
MA20
8.821
Sell
MA50
9.055
Sell
MA100
9.544
Sell
MA200
9.637
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEOKinney (Gene G)
Websitehttps://www.prothena.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52760.200
+382.200 (+0.73%)
28495.900
+335.000 (+1.19%)
7531.100
+56.000 (+0.75%)
14594.000
-155.000 (-1.05%)
63768.000
+916.000 (+1.46%)
6399.000
+33.600 (+0.53%)
78.090
-7.844 (-9.13%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4065.180
+23.750 (+0.59%)
FAQs
What is the current price of Prothena Corporation PLC (PRTA)?
The current price of Prothena Corporation PLC (PRTA) is 8.12.
What is the symbol of Prothena Corporation PLC?
The ticker symbol of Prothena Corporation PLC is PRTA.
What is the 52-week high of Prothena Corporation PLC?
The 52-week high of Prothena Corporation PLC is 11.80.
What is the 52-week low of Prothena Corporation PLC?
The 52-week low of Prothena Corporation PLC is 4.42.
What is the market capitalization of Prothena Corporation PLC?
The market capitalization of Prothena Corporation PLC is 425.11M.
Is Prothena Corporation PLC (PRTA) currently rated as Buy, Hold, or Sell?
According to analysts, Prothena Corporation PLC (PRTA) has an overall rating of signal_hold, with a price target of 21.40.
What is the Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA)?
The Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA) is -4.53.